Genprex, Inc. (ticker: GNPX) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of GNPX's SEC filings surfaces 6 active risk signals, including 5 late-filing signals, and 1 auditor-change signal. GNPX reported $0 in revenue and -$4.46M for the period ending 2024-12-31, with operating cash flow of -$3.14M. Cash and equivalents stood at $18.05M (up 420.4% year-over-year). Total assets of $20.31M exceed total liabilities of $3.38M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
GNPX SEC Filings
Full cached SEC EDGAR filing history for GNPX, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.